Table: Taisho Pharmaceutical HD -Q1 group results
Aug 3 (Reuters)-
Taisho Pharmaceutical Holdings Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Jun 30, 2022 Jun 30, 2021 Mar 31, 2023
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 69.07 63.88 280.50
(+8.1 pct) (-14.8 pct) (+4.6 pct)
Operating 5.25 2.68 16.00
(+96.3 pct) (-71.5 pct) (+48.9 pct)
Recurring 9.25 4.03 20.00
(+129.2 pct) (-63.7 pct) (+8.6 pct)
Net 5.75 1.18 12.00
(+387.6 pct) (-80.5 pct) (-8.6 pct)
EPS 70.16 yen 14.78 yen 146.26 yen
EPS Diluted 70.08 yen 14.75 yen
Ann Div 100.00 yen 100.00 yen
-Q2 div 50.00 yen 50.00 yen
-Q4 div 50.00 yen 50.00 yen
NOTE - Taisho Pharmaceutical Holdings Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4581.T
Recent news on Taisho Pharmaceutical Holdings Co
See all newsBrief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Squeeze Out Price If Taisho Disagrees With Their Demand - Nikkei
Brief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Tender Offer Price If Taisho Disagrees Their Demand - Nikkei
Activist fund Oasis says it may take legal action over Taisho's management buyout
Brief: Curi RMB Capital Opposes Taisho Pharmaceutical HD's Management Buyout
To Retire Treasury Shares Worth 3.65% Of Outstanding Stock On April 10